BioSpace News Archive

Extension in inescapability of constant ailment and rise famous for mHealth and wearable contraptions drive the advancement of the overall computerized digital health market.

Rise in importance of vital signs monitoring devices in home care settings and improved reimbursement scenario in developed countries drive growth of the global vital signs monitoring devices market.

For more information regarding the conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact KCSA Strategic Communications at Awakn@KCSA.com or your Canaccord Genuity’s representatives directly.

Biocom California, the association representing the California life science industry, today announced a call for entries for the sixth annual Life Science Catalyst Awards.

Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease progression in patients with metabolic acidosis and CKD, announced financial results for the three and six months ended June 30, 2021 and provided an update on key initiatives.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) (“the Company”), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2021 financial results.

Ziopharm Oncology, Inc., provided corporate updates for the second quarter of 2021, ended June 30, 2021.

“We continued to deliver consistent growth and progress in the second quarter with the core NUZYRA commercial business seeing quarter over quarter growth, as net sales increased 13% to $14.9 million versus the first quarter,” said Evan Loh, M.D., Chief Executive Officer at Paratek.

Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superiority over trastuzumab emtansine (T-DM1).

Dr. Stene brings a record of accomplishment in guiding biotech companies through the process of achieving clinical laboratory accreditation.